PHOTOCURE ASA (PHO.OL) Stock Price, Forecast & Analysis
Europe - Euronext Oslo - OSL:PHO - NO0010000045 - Common Stock
PHO.OL Key Statistics, Chart & Performance
The current stock price of PHO.OL is 74.8 NOK. In the past month the price increased by 17.85%. In the past year, price increased by 28.4%.
PHO.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 10.84 | 200.10B | ||
| SNW.DE | SANOFI | 10.83 | 199.86B | ||
| 1SAN.MI | SANOFI | 10.69 | 197.40B | ||
| MRK.DE | MERCK KGAA | 14.94 | 55.41B | ||
| UCB.BR | UCB SA | 39.73 | 49.61B | ||
| UNC.DE | UCB SA | 38.68 | 48.30B | ||
| 1BAYN.MI | BAYER AG-REG | 7.12 | 37.38B | ||
| BAYN.DE | BAYER AG-REG | 7.18 | 37.64B | ||
| IPN.PA | IPSEN | 11.72 | 10.09B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 109.13 | 10.10B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.39 | 10.05B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 21.2 | 8.94B |
Related stock screener links
About PHO.OL
Company Profile
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 101 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Company Info
PHOTOCURE ASA
Hoffsveien 4
Oslo OSLO NO
Employees: 100
Phone: 4722062210
PHOTOCURE ASA / PHO.OL FAQ
What does PHO do?
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 101 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
What is the stock price of PHOTOCURE ASA today?
The current stock price of PHO.OL is 74.8 NOK. The price increased by 0.27% in the last trading session.
What is the dividend status of PHOTOCURE ASA?
PHO.OL does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHO stock?
PHO.OL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of PHOTOCURE ASA (PHO.OL)?
The PE ratio for PHOTOCURE ASA (PHO.OL) is 2493.33. This is based on the reported non-GAAP earnings per share of 0.03 and the current share price of 74.8 NOK.
Would investing in PHOTOCURE ASA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHO.OL.
When does PHOTOCURE ASA (PHO.OL) report earnings?
PHOTOCURE ASA (PHO.OL) will report earnings on 2026-02-17, after the market close.
PHO.OL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PHO.OL. When comparing the yearly performance of all stocks, PHO.OL is one of the better performing stocks in the market, outperforming 84.76% of all stocks.
PHO.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL. PHO.OL has a great financial health rating, but its profitability evaluates not so good.
PHO.OL Financial Highlights
Over the last trailing twelve months PHO.OL reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS decreased by -93.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| Debt/Equity | 0 |
PHO.OL Forecast & Estimates
8 analysts have analysed PHO.OL and the average price target is 81.6 NOK. This implies a price increase of 9.09% is expected in the next year compared to the current price of 74.8.
For the next year, analysts expect an EPS growth of 916.42% and a revenue growth 12.38% for PHO.OL